Gastroenteritis: Clinical Trials

389 trials for Gastroenteritis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

389 completed. 389 Phase 3, 44 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3389Completed 389
Phase 244Completed 44

Follow Gastroenteritis: new trials by email Literature Review of Gastroenteritis trials Research Report on Gastroenteritis

Trials (filtered) newest first · largest first

All 389 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication
Vonoprazan, Amoxicillin, Clarithromycin - Helicobacter Pylori Infection, Gastritis
Phase 3CompletedAlexandria University3262024-06-302025-02-11
The Effects of Bromelain Supplement in Patients With Ulcerative Colitis
Bromlein, Placebo - Ulcerative Colitis, Primary Sclerosing Cholangitis
Phase 2 / Phase 3CompletedNational Nutrition and Food Technology Institute522024-04-202026-10-27
A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants
HRV PCV-free, IPV - Gastroenteritis
Phase 3CompletedGlaxoSmithKline4002024-03-222025-10-22
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
Mirikizumab IV, Mirikizumab SC - Ulcerative Colitis
Phase 3CompletedEli Lilly and Company632023-11-222026-06-03
Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks
GSK's liquid oral live attenuated HRV, PCV-free liquid formulation of GSK's oral live attenuated HRV - Gastroenteritis
Phase 3CompletedGlaxoSmithKline20002023-09-012025-05-09
Dapagliflozin in Patients With Ulcerative Colitis
Mesalamine, Dapagliflozin 10mg Tab - Inflammatory Bowel Diseases
Phase 2 / Phase 3CompletedMostafa Bahaa602023-08-202026-09-21
Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis
Mesalamine, Nifuroxazide - Inflammatory Bowel Diseases
Phase 2 / Phase 3CompletedMostafa Bahaa502023-08-202026-10-13
Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines
HIL-214, Placebo - Gastroenteritis
Phase 2 / Phase 3CompletedHilleVax3292023-06-102025-03-12
Comparison of Ketorolac at Three Doses in Children With Acute Pain
Ketorolac Tromethamine - Acute Pain, Abdominal Pain
Phase 3CompletedHamilton Health Sciences Corporation1712023-06-012025-07-09
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
Mirikizumab - Ulcerative Colitis, Ulcerative Colitis Chronic
Phase 3CompletedEli Lilly and Company1722023-05-172026-06-10
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
RBX2660 - Clostridium Difficile Infection Recurrence
Phase 3CompletedFerring Pharmaceuticals412023-04-212026-04-24
Fenofibrate in Ulcerative Colitis
Mesalamine, Fenofibrate 160mg - Inflammatory Bowel Diseases
Phase 2 / Phase 3CompletedTanta University602023-02-282026-05-04
Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure
polyethylene glycol, sodium phosphate, polyethylene glycol + ascorbic acid - Colon Cancer, Inflammatory Bowel Diseases
Phase 3CompletedRegion Skane1472023-02-012024-02-28
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
ABX464, Placebo - Ulcerative Colitis
Phase 3CompletedAbivax S.A.6362023-01-252026-09-10
24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy - Eosinophilic Esophagitis
Phase 3CompletedEllodi Pharmaceuticals, LP2182022-12-292025-08-13
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
ABX464, Placebo - Ulcerative Colitis
Phase 3CompletedAbivax S.A.6392022-11-162026-09-10
Cholecalciferol Comedication in IBD - the 5C-study
Vitamin D3 - Inflammatory Bowel Diseases
Phase 3CompletedUniversity Hospital, Basel, Switzerland1502022-09-212024-12-24
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
CC-93538 - Eosinophilic Esophagitis
Phase 3CompletedCelgene3672022-08-092026-04-06
Effect of Pentoxifylline Versus Probiotic on Preterm Neonates With Necrotizing Enterocolitis
Pentoxifylline, Probiotic Formula - Necrotizing Enterocolitis
Phase 3CompletedTanta University752022-06-302024-05-20
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis
CC-93538, Placebo - Eosinophilic Gastroenteritis
Phase 3CompletedCelgene482022-03-042026-09-14

Showing 20 of 389. Sign in to see all of them.

Narrower conditions

Colitis, Ulcerative (123)  ·  Crohn Disease (122)  ·  Inflammatory Bowel Diseases (48)  ·  Eosinophilic Esophagitis (20)  ·  Diarrhea (18)  ·  Esophagitis, Peptic (15)  ·  Mucositis (15)  ·  Colitis (14)  ·  Appendicitis (12)  ·  Gastrointestinal Diseases (12)  ·  Esophagitis (10)  ·  Enterocolitis, Necrotizing (9)  ·  Gastroesophageal Reflux (8)  ·  Diverticulitis (7)

Broader conditions

Digestive System Diseases (383)  ·  Gastrointestinal Diseases (377)  ·  Intestinal Diseases (310)  ·  Inflammatory Bowel Diseases (202)  ·  Colonic Diseases (134)  ·  Colitis (119)  ·  Pathological Conditions, Signs and Symptoms (54)  ·  Infections (40)  ·  Esophageal Diseases (33)  ·  Hemic and Lymphatic Diseases (32)  ·  Esophagitis (29)  ·  Hematologic Diseases (28)  ·  Signs and Symptoms (27)  ·  Immune System Diseases (26)

Interventions

Mesalamine (41)  ·  Adalimumab (34)  ·  Budesonide (18)  ·  Infliximab (18)  ·  Certolizumab Pegol (10)  ·  Ustekinumab (10)  ·  vedolizumab (10)  ·  Probiotics (7)  ·  Lansoprazole (6)  ·  etrolizumab (6)  ·  Azathioprine (5)  ·  Dexlansoprazole (5)  ·  Esomeprazole (5)  ·  Fluticasone (5)  ·  mirikizumab (5)

Sponsors

Takeda (16)  ·  AbbVie (14)  ·  Abbott (14)  ·  Bausch Health Americas, Inc. (14)  ·  Dr. Falk Pharma GmbH (12)  ·  Shire (11)  ·  Centocor, Inc. (8)  ·  Ferring Pharmaceuticals (8)  ·  Janssen Research & Development, LLC (8)  ·  Celgene (7)  ·  UCB Pharma (7)  ·  AstraZeneca (6)  ·  GlaxoSmithKline (6)  ·  Hoffmann-La Roche (6)  ·  Pfizer (6)

Countries

United States (188)  ·  Canada (126)  ·  Germany (103)  ·  Belgium (92)  ·  Poland (89)  ·  United Kingdom (80)  ·  France (79)  ·  Czechia (77)  ·  Italy (76)  ·  Israel (74)  ·  Australia (72)  ·  Hungary (72)  ·  Spain (67)  ·  Japan (64)  ·  Netherlands (63)

Results publications

PMID 29380251, PMID 32445184, PMID 37368103, PMID 19735233, PMID 20195905, PMID 26893500, PMID 29850873, PMID 30476584, PMID 31077827, PMID 31599001, PMID 32635680, PMID 32766762, PMID 32816215, PMID 32870265, PMID 32964215, PMID 33324993, PMID 33684552, PMID 34614208, PMID 35648151, PMID 35792493, PMID 36124702, PMID 36336750, PMID 36342120, PMID 36526796, PMID 36931693, PMID 37402275, PMID 37560161, PMID 38310565, PMID 38425446, PMID 40357993, PMID 21129076, PMID 25996351, PMID 26563167, PMID 27959607, PMID 28467869, PMID 29028981, PMID 29142515, PMID 29409871, PMID 29743836, PMID 29857145, PMID 29909019, PMID 30203005, PMID 30739254, PMID 31279870, PMID 33127596, PMID 33513294, PMID 34035832, PMID 34077627, PMID 34165201, PMID 35380664

NIH funding

2015 (10), 2016 (10), 2017 (10), 2004 (6), 2014 (6), 2018 (6), 2019 (6), 2008 (5), 2023 (3), 2005 (2), 2009 (1), K01DK075478 (1), M01RR000070 (1), M01RR000997 (1), P30CA068485 (1)